Artificial Tears Market Report 2026

Artificial Tears Market Report 2026
Global Outlook – By Type (Glycerin Tears, Cellulose Tears, Oil-Based Emulsion Tears, Polyethylene Glycol-based Tears, Sodium Hyaluronate Based Artificial Tears, Propylene Glycol-based Tears), By Dosage (Suspensions, Solution, Ointment, Emulsion, Gel), By Indication (Dry Eye Syndrome, Contact Lens Moisture Retention, Other Indications), By Distribution (Retail Pharmacies, Hospital Pharmacies, Online Pharmacies, Ophthalmic Stores) – Market Size, Trends, Strategies, and Forecast to 2035
Artificial Tears Market Overview
• Artificial Tears market size has reached to $3.74 billion in 2025 • Expected to grow to $5.07 billion in 2030 at a compound annual growth rate (CAGR) of 6.3% • Growth Driver: Artificial Tears Demand Soars As Dry Eye Disease Prevalence Increases • Market Trend: Innovative Preservative-Free Solutions Driving Advancements In The Artificial Tears Market • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.What Is Covered Under Artificial Tears Market?
Artificial tears are eye drops, gels, or ointments that are used to relieve dryness and irritation of the ocular surface. It is commonly used to treat dry eye syndrome, a condition caused by reduced tear production or increased tear evaporation. The main types of artificial tears are glycerin tears, cellulose tears, oil-based emulsion tears, polyethylene glycol-based tears, sodium hyaluronate-based artificial tears, and propylene glycol-based tears. Glycerin refers to a component of some artificial tears used to relieve dry, irritated eyes. The various dosages include suspensions, solution, ointment, emulsion, gel, and spray. The various indications include dry eye syndrome, allergies, infections, UV and blue light protection, contact lens moisture retention, and others. These are distributed by various distribution channels such as retail pharmacies, hospital pharmacies, online pharmacies, and ophthalmic stores.
What Is The Artificial Tears Market Size and Share 2026?
The artificial tears market size has grown strongly in recent years. It will grow from $3.74 billion in 2025 to $3.97 billion in 2026 at a compound annual growth rate (CAGR) of 6.1%. The growth in the historic period can be attributed to increasing incidence of dry eye syndrome, rising use of contact lenses, growing awareness about eye care, development of multi-purpose eye drops, presence of major market players.What Is The Artificial Tears Market Growth Forecast?
The artificial tears market size is expected to see strong growth in the next few years. It will grow to $5.07 billion in 2030 at a compound annual growth rate (CAGR) of 6.3%. The growth in the forecast period can be attributed to innovation in preservative-free and high molecular weight formulations, growth of e-commerce and online pharmacy channels, increasing geriatric population, technological advancements in drug delivery, expansion in emerging markets. Major trends in the forecast period include growth in prescription and over-the-counter eye drops, rising prevalence of dry eye syndrome, increasing awareness of eye health and preventive care, development of preservative-free formulations, expansion of online pharmacy and e-commerce channels.Global Artificial Tears Market Segmentation
1) By Type: Glycerin Tears, Cellulose Tears, Oil-Based Emulsion Tears, Polyethylene Glycol-based Tears, Sodium Hyaluronate Based Artificial Tears, Propylene Glycol-based Tears 2) By Dosage: Suspensions, Solution, Ointment, Emulsion, Gel 3) By Indication: Dry Eye Syndrome, Contact Lens Moisture Retention, Other Indications 4) By Distribution: Retail Pharmacies, Hospital Pharmacies, Online Pharmacies, Ophthalmic Stores Subsegments: 1) By Glycerin Tears: Preserved Glycerin Tears, Preservative-Free Glycerin Tears 2) By Cellulose Tears: Hydroxypropyl Methylcellulose (HPMC) Tears, Carboxymethylcellulose (CMC) Tears 3) By Oil-Based Emulsion Tears: Mineral Oil-based Tears, Castor Oil-based Tears 4) By Polyethylene Glycol-based Tears: PEG 400 Tears, PEG 3350 Tears 5) By Sodium Hyaluronate Based Artificial Tears: Low Molecular Weight Sodium Hyaluronate Tears, High Molecular Weight Sodium Hyaluronate Tears 6) By Propylene Glycol-based Tears: Preserved Propylene Glycol Tears, Preservative-Free Propylene Glycol TearsWhat Is The Driver Of The Artificial Tears Market?
The rising prevalence of dry eye disease is expected to propel the growth of the artificial tear market going forward. Dry eye disease is a condition where the eyes do not produce enough tears, or the tears are of poor quality, leading to irritation and discomfort. Artificial tears supplement natural tear production, providing lubrication and relief for dry eyes. For instance, in February 2024, according to the Eyes On Eyecare is a US-based, digital media and education company, the clinical focus on dry eye is projected to rise by 13.89%, increasing from 37.23% in 2023 to 42.4% in 2024. Therefore, the rising prevalence of dry eye disease is driving the growth of the artificial tear industry.Key Players In The Global Artificial Tears Market
Major companies operating in the artificial tears market are Pfizer Inc, Johnson & Johnson, AbbVie Inc, Novartis AG, Abbott Laboratories, Otsuka Pharmaceutical Co Ltd, Alcon, Bausch Health Companies Inc, Sun Pharmaceutical Industries Ltd, Dr Reddys Laboratories Ltd, Santen Pharmaceutical Co Ltd, Lupin Limited, Rohto Pharmaceutical Co Ltd, Prestige Consumer Healthcare Inc, Thea Pharma Inc, Sentiss Pharma Pvt Ltd, VISUfarma BV, Similasan Corporation, Eyevance Pharmaceuticals LLC, Nicox SA, I MED Pharma Inc, Velocity Pharma LLCGlobal Artificial Tears Market Trends and Insights
Major companies operating in the artificial tears market are focusing on developing advanced preservative-free formulations to improve ocular comfort, reduce irritation, and enhance treatment adherence for patients with dry eye disease. Preservative-free eye drops are designed to minimize ocular surface toxicity and provide safer long-term use. For instance, in February 2025, Alcon Inc., a Switzerland-based eye care company, launched Systane Pro PF, aimed at alleviating symptoms of dry eye and improving overall ocular health. The product offers enhanced lubrication and relief, catering to patients with sensitive eyes and chronic dry eye conditions. This launch underscores the growing emphasis on patient-centric, safer, and more effective therapies in the artificial tears market.What Are Latest Mergers And Acquisitions In The Artificial Tears Market?
In July 2023, Bausch + Lomb, a Canada-based eye health products company, acquired the Blink products line of Johnson & Johnson for $106.5 million. Through this acquisition, Bausch + Lomb seeks to enhance its portfolio in the over-the-counter (OTC) eye care sector, offering greater consumer convenience and a broader range of eye care solutions. Blink is a US-based pharmaceutical company offering tears lubricating eye drops.Regional Insights
North America was the largest region in the artificial tears market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.What Defines the Artificial Tears Market?
The artificial tears market consists of sales of blink tears, soothe XP, genteal tears, and visine tears. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.How is Market Value Defined and Measured?
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.What Key Data and Analysis Are Included in the Artificial Tears Market Report 2026?
The artificial tears market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the artificial tears industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.Artificial Tears Market Report Forecast Analysis
| Report Attribute | Details |
|---|---|
| Market Size Value In 2026 | $3.97 billion |
| Revenue Forecast In 2035 | $5.07 billion |
| Growth Rate | CAGR of 6.1% from 2026 to 2035 |
| Base Year For Estimation | 2025 |
| Actual Estimates/Historical Data | 2020-2025 |
| Forecast Period | 2026 - 2030 - 2035 |
| Market Representation | Revenue in USD Billion and CAGR from 2026 to 2035 |
| Segments Covered | Type, Dosage, Indication, Distribution |
| Regional Scope | Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa |
| Country Scope | The countries covered in the report are Australia, Brazil, China, France, Germany, India, ... |
| Key Companies Profiled | Pfizer Inc, Johnson & Johnson, AbbVie Inc, Novartis AG, Abbott Laboratories, Otsuka Pharmaceutical Co Ltd, Alcon, Bausch Health Companies Inc, Sun Pharmaceutical Industries Ltd, Dr Reddys Laboratories Ltd, Santen Pharmaceutical Co Ltd, Lupin Limited, Rohto Pharmaceutical Co Ltd, Prestige Consumer Healthcare Inc, Thea Pharma Inc, Sentiss Pharma Pvt Ltd, VISUfarma BV, Similasan Corporation, Eyevance Pharmaceuticals LLC, Nicox SA, I MED Pharma Inc, Velocity Pharma LLC |
| Customization Scope | Request for Customization |
| Pricing And Purchase Options | Explore Purchase Options |
Frequently Asked Questions
The Artificial Tears market was valued at $3.74 billion in 2025, increased to $3.97 billion in 2026, and is projected to reach $5.07 billion by 2030.
request a sample hereThe global Artificial Tears market is expected to grow at a CAGR of 6.3% from 2026 to 2035 to reach $5.07 billion by 2035.
request a sample hereSome Key Players in the Artificial Tears market Include, Pfizer Inc, Johnson & Johnson, AbbVie Inc, Novartis AG, Abbott Laboratories, Otsuka Pharmaceutical Co Ltd, Alcon, Bausch Health Companies Inc, Sun Pharmaceutical Industries Ltd, Dr Reddys Laboratories Ltd, Santen Pharmaceutical Co Ltd, Lupin Limited, Rohto Pharmaceutical Co Ltd, Prestige Consumer Healthcare Inc, Thea Pharma Inc, Sentiss Pharma Pvt Ltd, VISUfarma BV, Similasan Corporation, Eyevance Pharmaceuticals LLC, Nicox SA, I MED Pharma Inc, Velocity Pharma LLC .
request a sample hereMajor trend in this market includes: Innovative Preservative-Free Solutions Driving Advancements In The Artificial Tears Market . For further insights on this market.
request a sample hereNorth America was the largest region in the artificial tears market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the artificial tears market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
request a sample here